Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 28, 2014; 20(32): 11384-11393
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11384
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11384
Table 2 Other treatment or medication for recurrent hepatocellular carcinoma during the 156 wk follow-up period n (%)
| Anti-HCC therapy | Group A untreated (n = 58) | Group B 160 mg/d (n = 56) | Group C 250 mg/d (n = 54) | Total (n = 168) |
| At least one shown below | 22 (37.9) | 17 (30.4) | 22 (40.7) | 61 (36.3) |
| Chemotherapy | 3 (5.2) | 4 (7.1) | 4 (7.4) | 11 (6.5) |
| Percutaneous ethanol injection therapy | 2 (3.4) | 3 (5.4) | 3 (5.6) | 8 (4.8) |
| Radiofrequency ablation | 2 (3.4) | 3 (5.4) | 3 (5.6) | 8 (4.8) |
| Radiotherapy | 3 (5.2) | 1 (1.8) | 1 (1.9) | 5 (3.0) |
| Surgical resection | 5 (8.6) | 5 (8.9) | 7 (13.0) | 17 (10.1) |
| Transcatheter arterial chemoembolization | 18 (31.0) | 11 (19.6) | 15 (27.8) | 44 (26.2) |
| Thalidomide | 2 (3.4) | 1 (1.8) | 1 (1.9) | 4 (2.4) |
| Liver transplantation | 0 (0.0) | 1 (1.8) | 1 (1.9) | 2 (1.2) |
| Sorafenib | 1 (1.7) | 1 (1.8) | 1 (1.9) | 3 (1.8) |
| New clinical trial | 3 (5.1) | 1 (1.8) | 6 (11.3) | 10 (6.0) |
- Citation: Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SSC, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(32): 11384-11393
- URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11384.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11384